GlassScriptPhysician profile
Amanda Estrada
NPI 1578206603
$948.10
in general payments reported to CMS, 2019-2025
11 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $271 · 2024: $445 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $302.57 | 2023-2025 | Qutenza |
| Boston Scientific Corporation | $143.84 | 2025 | Intracept |
| Vertex Pharmaceuticals Incorporated | $109.49 | 2024-2025 | |
| Pfizer INC. | $97.41 | 2023-2025 | |
| Abbvie INC. | $87.20 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $68.00 | 2024 | |
| Collegium Pharmaceutical, INC. | $63.77 | 2023 | Belbuca |
| Ultragenyx Pharmaceutical INC. | $24.31 | 2023 | |
| Idorsia Pharmaceuticals US INC | $19.47 | 2023 | Quviviq |
| Bioventus LLC | $17.89 | 2023 | Durolane |
| Ibsa Pharma INC. | $14.15 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Estrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.